Toronto Dominion Bank Buys New Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Toronto Dominion Bank acquired a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 3,173,258 shares of the company's stock, valued at approximately $35,001,000. Toronto Dominion Bank owned about 5.99% of Stoke Therapeutics as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new position in Stoke Therapeutics during the 4th quarter worth $63,000. Teacher Retirement System of Texas purchased a new stake in shares of Stoke Therapeutics in the fourth quarter valued at about $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Stoke Therapeutics in the fourth quarter valued at about $124,000. Tower Research Capital LLC TRC boosted its holdings in shares of Stoke Therapeutics by 70.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after acquiring an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. purchased a new stake in shares of Stoke Therapeutics in the fourth quarter valued at about $133,000.

Stoke Therapeutics Stock Performance

STOK stock traded down $0.14 during trading on Friday, reaching $9.36. 471,276 shares of the company were exchanged, compared to its average volume of 712,129. The company has a market cap of $511.03 million, a P/E ratio of -4.46 and a beta of 1.20. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $17.58. The stock's 50 day moving average price is $8.26 and its 200 day moving average price is $9.85.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to analysts' expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on STOK. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. HC Wainwright lowered their target price on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Chardan Capital reaffirmed a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $23.20.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. The trade was a 5.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. The trade was a 6.54% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,532 shares of company stock worth $143,332. Insiders own 11.30% of the company's stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.